Thermo Fisher Q3 2026 Earnings: Revenue Rises 9% as Operating Margins Expand

Thermo Fisher Scientific (NYSE: TMO) reported Q3 2026 revenue of $12.14 billion, up 9% year over year, and GAAP diluted EPS of $4.64, also up 9% from $4.27. Adjusted EPS rose 15% to $6.68 as both GAAP and adjusted operating margins expanded by 120 basis points, while free cash flow increased approximately 15% to $2.12 billion.

Core Earnings Data

For the quarter ended September 26, organic revenue grew 6%, while acquisitions and divestitures contributed another 3 percentage points and currency translation had no effect. Operating profit grew faster than revenue under both GAAP and adjusted measures.

Lower cost-of-revenue and SG&A ratios supported the margin improvement. Cost of revenue declined to 57.2% of sales from 58.2%, while SG&A fell to 15.3% from 16.1%.

Business and Segment Performance

Laboratory Products and Biopharma Services supplied most of the revenue increase, while Analytical Instruments recorded the largest margin expansion. Specialty Diagnostics was the only segment with lower revenue, but its segment profit and margin still improved.

Laboratory Products and Biopharma Services added $893 million of revenue and increased segment income by approximately 23% to $1.07 billion. Its margin rose 100 basis points to 15.5%, making it the primary driver of consolidated growth.

Analytical Instruments increased segment income by approximately 25% despite revenue growth of about 6%, lifting its margin by 430 basis points. Specialty Diagnostics showed a similar revenue-profit divergence: revenue declined, but segment income rose approximately 6% and margin expanded by 360 basis points. The release did not provide a specific explanation for this divergence.

Thermo Fisher also launched products spanning mass spectrometry, electron microscopy, autoimmune testing and sequencing. Other commercial developments included the Precure initiative with Mayo Clinic, an AI-Automation Innovation Center in South Korea and a new automated distribution center in Kentucky. The company completed the divestiture of its microbiology business during the quarter.

Profitability, Cash Flow and Balance Sheet

GAAP operating margin expanded even though acquisition-related intangible amortization increased to $519 million from $435 million and restructuring and other costs rose to $199 million from $135 million. These items were among the main reasons adjusted EPS exceeded GAAP EPS by $2.04. The restructuring adjustments included a $244 million held-for-sale loss and a $72 million gain on the sale of a business.

Cash conversion also improved. Quarterly free cash flow rose to $2.12 billion even as capital spending increased to $437 million from $404 million. For the first nine months of 2026, which is a separate year-to-date measure, operating cash flow reached $5.87 billion and free cash flow was $4.62 billion, compared with $4.36 billion and $3.32 billion, respectively, in the prior-year period.

At September 26, cash and equivalents stood at $5.46 billion, down from $9.85 billion at the end of 2025. Long-term obligations increased to $39.11 billion from $35.85 billion, while short-term obligations and current maturities declined to $2.26 billion from $3.53 billion. The combination of stronger cash generation, lower cash balances and higher long-term obligations makes capital deployment an important area to monitor.

Investor Risks to Watch

• Specialty Diagnostics revenue pressure: The segment’s revenue fell approximately 6% even as profitability improved. Continued contraction could eventually make further profit growth more difficult.
• Difference between reported and organic growth: Organic revenue rose 6% compared with reported growth of 9%, with acquisitions and divestitures contributing 3 percentage points. Investors should distinguish operating momentum from portfolio-related growth.
• GAAP and adjusted earnings gap: Higher acquisition-related amortization and restructuring costs created a meaningful difference between GAAP and adjusted EPS. The size and persistence of these adjustments remain relevant to reported profitability.
• Balance-sheet movement: Cash declined and long-term obligations increased from year-end 2025, despite stronger quarterly and year-to-date cash flow.

Summary

Thermo Fisher’s Q3 2026 results combined 9% reported revenue growth and 6% organic growth with faster gains in operating income, EPS and free cash flow. Laboratory Products and Biopharma Services was the main growth engine, while Analytical Instruments delivered the strongest margin improvement and Specialty Diagnostics posted lower revenue. The key follow-up points are the durability of organic growth and margin expansion, the revenue trajectory in Specialty Diagnostics and how future capital deployment affects cash and obligations.